BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17956707)

  • 1. [Biotherapy of cancer by anti-EGFR monoclonal antibody].
    Wang J; Meng ZY; Fu ST; Dou GF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1135-8. PubMed ID: 17956707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New trends in epidermal growth factor receptor-directed monoclonal antibodies.
    Markman B; Capdevila J; Elez E; Tabernero J
    Immunotherapy; 2009 Nov; 1(6):965-82. PubMed ID: 20635913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
    Heun J; Holen K
    Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; BarĂ³n AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
    Cohenuram M; Saif MW
    Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
    Herbst RS; Hong WK
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer.
    Kim S; Grandis JR; Rinaldo A; Takes RP; Ferlito A
    Head Neck; 2008 May; 30(5):667-74. PubMed ID: 18383530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EGFR in colorectal cancer.
    Messersmith WA; Ahnen DJ
    N Engl J Med; 2008 Oct; 359(17):1834-6. PubMed ID: 18946069
    [No Abstract]   [Full Text] [Related]  

  • 19. Epidermal growth factor receptor targeted therapies for solid tumours.
    Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
    Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidermal growth factor receptor as a target for colorectal cancer therapy.
    Lockhart AC; Berlin JD
    Semin Oncol; 2005 Feb; 32(1):52-60. PubMed ID: 15726506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.